Issues affecting art success adherence arv toxicity drug interactions
This presentation is the property of its rightful owner.
Sponsored Links
1 / 43

Issues Affecting ART Success: Adherence, ARV Toxicity, Drug Interactions PowerPoint PPT Presentation


  • 60 Views
  • Uploaded on
  • Presentation posted in: General

Issues Affecting ART Success: Adherence, ARV Toxicity, Drug Interactions. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents December 2009 AETC NRC Slide Set. About This Presentation.

Download Presentation

Issues Affecting ART Success: Adherence, ARV Toxicity, Drug Interactions

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Issues affecting art success adherence arv toxicity drug interactions

Issues Affecting ART Success: Adherence, ARV Toxicity, Drug Interactions

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents

December 2009

AETC NRC Slide Set


About this presentation

About This Presentation

These slides were developed using the December 2009 guidelines. The intended audience is clinicians involved in the care of patients with HIV.

Because the field of HIV care is rapidly changing, users are cautioned that the information in this presentation may become out of date quickly.

It is intended that these slides be used as prepared, without changes in either content or attribution. Users are asked to honor this intent.

– AETC NRChttp://www.aidsetc.org

www.aidsetc.org


Initiation of therapy contents

Initiation of Therapy: Contents

  • Adherence

  • ARV-associated adverse effects

  • Drug interactions

www.aidsetc.org


Adherence

Adherence

  • High adherence rates associated with virologic suppression, low rates of resistance, and improved survival

  • Important to assess readiness for ART prior to initiating therapy, and to assess adherence at each clinic visit

  • Suboptimal adherence is common

www.aidsetc.org


Predictors of inadequate adherence

Predictors of Inadequate Adherence

  • Regimen complexity and pill burden

  • Low literacy level

  • Active drug use or alcoholism

  • Stigma

  • Mental illness (especially depression)

  • Cognitive impairment

  • Lack of patient education

  • Medication adverse effects

  • Treatment fatigue

www.aidsetc.org


Predictors of inadequate adherence 2

Predictors of Inadequate Adherence (2)

  • Age, race, sex, educational level, socioeconomic status, and a past history of alcoholism or drug use do NOT reliably predict suboptimal adherence

  • Higher socioeconomic status and education levels and lack of history of drug use do NOT reliably predict optimal adherence

www.aidsetc.org


Measurement of adherence

Measurement of Adherence

  • No gold standard

  • Patient self-report overestimates adherence, but is associated with viral load responses and is most useful method in the clinic setting

    • Self-report of suboptimal adherence is strong indicator of nonadherence

www.aidsetc.org


Predictors of good adherence

Predictors of Good Adherence

  • Emotional and practical supports

  • Convenience of regimen

  • Understanding of the importance of adherence

  • Belief in efficacy of medications

  • Feeling comfortable taking medicationsin front of others

  • Keeping clinic appointments

  • Severity of symptoms or illness

www.aidsetc.org


Improving adherence

Improving Adherence

  • Establish readiness to start therapy

  • Provide education on medication dosing

  • Review potential side effects

  • Anticipate and treat side effects

  • Use educational aids including pictures, pillboxes, and calendars

www.aidsetc.org


Improving adherence 2

Improving Adherence (2)

  • Simplify regimens, dosing, and food requirements

  • Engage family, friends

  • Utilize team approach with nurses, pharmacists, and peer counselors

  • Provide accessible, trusting health careteam

www.aidsetc.org


Art associated adverse effects

ART-Associated Adverse Effects

  • Lactic acidosis/hepatic steatosis

  • Hepatotoxicity

  • Insulin resistance, diabetes melitis

  • Fat maldistribution

  • Hyperlipidemia

  • Cardiovascular and cerebrovascular effects

  • Increased bleeding in hemophiliacs

  • Osteonecrosis, osteopenia, osteoporosis

  • Rash

www.aidsetc.org


Adverse effects nrtis

All NRTIs:

Lactic acidosis and hepatic steatosis (highest incidence with d4T, then ddI and ZDV, lower with TDF, ABC, 3TC, and FTC)

Lipodystrophy(higher incidence with d4T)

Adverse Effects: NRTIs

www.aidsetc.org


Adverse effects nrtis 2

ABC

HSR*

Rash

Possible ↑ risk of MI

ddI

GI intolerance

Peripheral neuropathy

Pancreatitis

Possible noncirrhotic portal hypertension

Adverse Effects: NRTIs (2)

* Screen for HLA-B*5709 before treatment with ABC; ABC should not be given to patients who test positive for HLA-B*5709.

www.aidsetc.org


Adverse effects nrtis 3

Adverse Effects: NRTIs (3)

  • d4T

    • Peripheral neuropathy

    • Pancreatitis

  • TDF

    • Renal impairment

    • Possible decrease in bone mineral density

    • Headache

    • GI intolerance

  • ZDV

    • Headache

    • GI intolerance

    • Bone marrow suppression

www.aidsetc.org


Adverse effects nnrtis

All NNRTIs:

Rash, including Stevens-Johnson syndrome

Drug-drug interactions

EFV

Neuropsychiatric

Teratogenic in nonhuman primates + cases of neural tube defects in human infants after 1st-trimester exposure

NVP

Higher rate of rash

Hepatotoxicity (may be severe and life-threatening;risk higher in patients with higher CD4 counts at the time they start NVP)

Adverse Effects: NNRTIs

www.aidsetc.org


Adverse effects pis

All PIs:

Hyperlipidemia

Insulin resistance and diabetes

Lipodystrophy

Elevated LFTs

Possible increased risk of MI and CVA

Possibility of increased bleeding riskfor hemophiliacs

Drug-drug interactions

Adverse Effects: PIs

www.aidsetc.org


Adverse effects pis 2

ATV

Hyperbilirubinemia

PR prolongation

Nephrolithiasis

DRV

Rash

Liver toxicity

FPV

GI intolerance

Rash

Possible increased risk of MI

Adverse Effects: PIs (2)

www.aidsetc.org


Adverse effects pis 3

IDV

Nephrolithiasis

GI intolerance

LPV/r

GI intolerance

Possible increased risk of MI

PR and QT prolongation

NFV

Diarrhea

Adverse Effects: PIs (3)

www.aidsetc.org


Adverse effects pis 4

RTV

GI intolerance

Hepatitis

SQV

GI intolerance

TPV

GI intolerance

Rash

Hyperlipidemia

Liver toxicity

Cases of intracranial hemorrhage

Adverse Effects: PIs (4)

www.aidsetc.org


Adverse effects ii

RAL

Nausea

Headache

Diarrhea

CPK elevation

Adverse Effects: II

www.aidsetc.org


Adverse effects fusion inhibitor

Adverse Effects: Fusion Inhibitor

  • ENF

    • Injection-site reactions

    • HSR

    • Increased risk of bacterial pneumonia

www.aidsetc.org


Adverse effects ccr5 antagonist

Adverse Effects: CCR5 Antagonist

  • MVC

    • Drug-drug interactions

    • Abdominal pain

    • Upper respiratory tract infections

    • Cough

    • Hepatotoxicity

    • Musculoskeletal symptoms

    • Rash

    • Orthostatic hypotension

www.aidsetc.org


Arv associated adverse effects lactic acidosis hepatic steatosis

ARV-Associated Adverse Effects: Lactic Acidosis/Hepatic Steatosis

  • Rare, but high mortality

  • Evidently due to mitochondrial toxicity

  • Associated with NRTIs (especially d4T, ddI, ZDV)

  • More common in women, pregnancy, obesity

  • Clinical presentation variable: have high index of suspicion

  • Lactate >2-5 mmol/dL plus symptoms

  • Treatment: discontinue ARVs, supportive care

www.aidsetc.org


Arv associated adverse effects hepatotoxicity

ARV-Associated Adverse Effects: Hepatotoxicity

  • Severity variable: usually asymptomatic, may resolve without treatment interruption

  • May occur with any NNRTI or PI, most NRTIs, or MVC:

    • NVP: risk of severe hepatitis in first 18 weeks of use (monitor LFTs closely), increased risk in chronic hepatitis B and C, women, and high CD4 count at initiation of NVP (>250 cells/µL in women, >400 cells/µL in men)

    • PIs: especially RTV, TPV, perhaps DRV; increased risk in hepatitis B or C, ETOH, other hepatotoxins

www.aidsetc.org


Arv associated adverse effects insulin resistance diabetes

ARV-Associated Adverse Effects: Insulin Resistance, Diabetes

  • Insulin resistance, hyperglycemia, and diabetes associated with ZDV, d4T, some PIs, especially with chronic use

  • Mechanism not well understood

    • Insulin resistance, relative insulindeficiency

  • Screen regularly: fasting glucose

www.aidsetc.org


Arv associated adverse effects fat maldistribution

Lipodystrophy:

No uniform definition

Mechanism not well understood

Peripheral fat wasting more associated with NRTIs, especially thymidine analogues (d4T>ZDV, ddI>TDF, ABC, 3TC, FTC)

Central fat accumulation perhaps more associated with PIs, especially if used with thymidine analogues

May be associated with dyslipidemia, insulin resistance, lactic acidosis

Monitor closely; intervene early

Treatment: switching to other agents may slow or halt progression

ARV-Associated Adverse Effects: Fat Maldistribution

www.aidsetc.org


Arv associated adverse effects hyperlipidemia

Elevations in total cholesterol, LDL, and triglycerides

Elevation in HDL seen with some RTV-boosted PIs

Associated with all PIs (except ATV), d4T, EFV, NVP

Mechanism unknown

Concern for cardiovascular events, pancreatitis

Monitor regularly

Treatment: consider ARV switch; lipid-lowering agents (caution with PI + certain statins)

ARV-Associated Adverse Effects: Hyperlipidemia

www.aidsetc.org


Arv associated adverse effects cardiovascular and cerebrovascular effects

Increased risk of MI and CVA associated with PIs

Increased risk of MI associated with recent ABC use in some studies (data are not consistent)

Seen especially in patients with traditional cardiovascular risk factors

Assess and manage cardiovascular risk factors

Consider ARVs with less risk of cardiovascular events, especially in patients at high risk of cardiovascular disease

ARV-Associated Adverse Effects: Cardiovascular and Cerebrovascular Effects

www.aidsetc.org


Arv associated adverse effects bone abnormalities

Osteonecrosis (AVN)

Mechanism unknown

Associated with PIs; unclear whether caused by them

Other risk factors: corticosteroid treatment, alcohol abuse, hemoglobinopathies, hyperlipidemia, hypercoagulable states

Treatment: surgical treatment for severe disease

Osteopenia

Associated with various ARVs, particularly TDF, d4T

Other risk factors: low body weight, female, white or Asian, older age, alcohol or tobacco use, hypogonadism, vitamin D deficiency, corticosteroid exposure

Consider assessment by DEXA

Management: calcium + vitamin D, bisphosphonate, weight-bearing exercise, hormone replacement

ARV-Associated Adverse Effects: Bone Abnormalities

www.aidsetc.org


Arv associated adverse effects rash

ARV-Associated Adverse Effects: Rash

  • Most common with NNRTIs, especially NVP

    • Most cases mild to moderate, occurring in first 6 weeks of therapy; occasionally serious (eg, Stevens-Johnson syndrome)

    • No benefit of prophylactic steroids or antihistamines (increased risk with steroids)

  • NRTIs: especially ABC (consider hypersensitivity syndrome)

  • PIs: especially FPV, DRV, TPV

  • CCR5 antagonist: MVC

www.aidsetc.org


Arv associated adverse effects nephrotoxicity

ARV-Associated Adverse Effects: Nephrotoxicity

  • Associated with IDV, TDF

    • IDV: increased Cr, pyuria, hydronephrosis or renal atrophy

    • TDF: increased Cr, proteinuria, hypophosphatemia, hypokalemia, proteinuria

  • Increased risk in patients with renal disease, low CD4 count

  • Monitor Cr, other renal parameters

  • Management: stop the offending ARV + supportive care

www.aidsetc.org


Overlapping toxicities

Overlapping Toxicities

  • Peripheral neuropathy

    • ddI, d4T, ddC, isoniazid

  • Bone marrow suppression

    • ZDV, dapsone, hydroxyurea, ribavirin, TMP-SMZ

  • Hepatotoxicity

    • NVP, EFV, MVC, NRTIs, PIs, macrolides, isoniazid

  • Pancreatitis

    • ddI, RTV, d4T, TMP-SMZ, pentamidine

www.aidsetc.org


Drug interactions with arvs

Drug Interactions with ARVs

  • Certain ARVs, particularly PIs and NNRTIs, have significant drug interactions with other ARVs and with other medications

  • Interactions may be complex and difficult to predict

  • Coadministration of some ARVs with other ARV or non-ARV medications may require dose adjustment, and some combinations may be contraindicated

  • Check for interactions before prescribing

www.aidsetc.org


Drug interactions with arvs1

Drug Interactions with ARVs

  • Increases in serum drug levels caused by inhibitors of metabolism may increase risk of medication toxicity, while decreases in drug levels caused by inducers of metabolism may cause treatment failure

  • Some drug interactions may be exploited, eg, low-dose ritonavir (a strong CYP3A4 inhibitor) may be used as a pharmacokinetic enhancer to increase concentrations and prolong the half-life of other PIs

www.aidsetc.org


Drug interactions with arvs2

Drug Interactions with ARVs

  • All PIs and NNRTIs are metabolized by the hepatic CYP 450 system, particularly the CYP3A4

  • PIs

    • All PIs are CYP3A4 substrates, and their serum levels may be affected by CYP inducers or inhibitors

    • Some PIs also are inducers or inhibitors of other CYP isoenzymes or of P-glycoprotein (PGP) or other transporters

  • NNRTIs

    • Substrates of CYP3A4, can act as inducer (NVP) or mixed inducer and inhibitor (EFV)

    • ETR is substrate of 3A4, 2C9, and 2C19; and inhibitor of 2C9 and 2C19

www.aidsetc.org


Drug interactions with arvs3

Drug Interactions with ARVs

  • NRTIs

    • No hepatic metabolism, but some NRTIs may interact via other mechanisms (eg, decrease in ATV concentration if coadministered with TDF, proton pump inhibitors, H2 receptor antagonists)

  • Integrase inhibitor

    • RAL: eliminated by glucuronidation; inducers of UGT1A1 (eg, rifampin) can reduce RAL concentration

www.aidsetc.org


Drug interactions with arvs4

Drug Interactions with ARVs

  • CCR5 antagonist

    • MVC: substrate of CYP3A and PGP; concentrations are significantly affected by CYP3A inhibitors or inducers. Dosage adjustment necessary.

  • Fusion inhibitor

    • ENF: no known significant drug interactions

www.aidsetc.org


Common drug interactions with arvs require dosage modification or cautious use

Common Drug Interactions with ARVs: Require Dosage Modification or Cautious Use

  • Lipid-lowering agents

  • Antimycobacterials, especially rifampin*

  • Antifungals

  • Psychotropics – midazolam, triazolam

  • Ergot alkaloids

  • Antihistamines – astemizole

  • Anticonvulsants

* Of NNRTIs and PIs, rifampin may be used only with full-dose RTV or with EFV.

www.aidsetc.org


Common drug interactions with arvs require dosage modification or cautious use 2

Common Drug Interactions with ARVs: Require Dosage Modification or Cautious Use (2)

  • Oral contraceptives(may require second method)

  • Methadone

  • Erectile dysfunction agents

  • Herbs – St. John’s wort

www.aidsetc.org


Arv arv interactions require dosage modification or cautious use

ARV-ARV Interactions: Require Dosage Modification or Cautious Use

  • EFV, NVP, or ETR with PIs

  • ATV + TDF

  • ddI + TDF

  • ddI + d4T

  • MVC + many PIs

  • MVC + EFV or ETR

www.aidsetc.org


Arv arv interactions

ARV-ARV Interactions

  • Interactions involving ARVs often require dose adjustment of the ARV and/or the interacting medication

  • Some combinations are contraindicated

  • Consider the possibility of interactions whenever adding a new medication

  • Consult with expert pharmacists or clinicians

www.aidsetc.org


Websites to access the guidelines

Websites to Access the Guidelines

  • http://www.aidsetc.org

  • http://aidsinfo.nih.gov

www.aidsetc.org


About this slide set

About This Slide Set

  • This presentation was prepared by Susa Coffey, MD, for the AETC National Resource Center in December 2009.

  • See the AETC NRC website for the most current version of this presentation: http://www.aidsetc.org

www.aidsetc.org


  • Login